FY2027 EPS Estimates for Astrazeneca Reduced by Analyst

Key Points

• Erste Group Bank lowered AstraZeneca’s FY2027 EPS estimate to $11.42 from $11.50, though it remains above the broader consensus estimate of $10.22.
• Analyst sentiment is mixed: several firms recently downgraded the stock to “Hold,” but AstraZeneca retains a “Moderate Buy” consensus rating and a $211 average price target.
• AstraZeneca’s latest quarterly results beat EPS expectations at $2.63 versus $2.50, while revenue rose 6.4% year over year to $15.38 billion, slightly below estimates.

Astrazeneca Plc (NYSE:AZN - Free Report) - Equities research analysts at Erste Group Bank dropped their FY2027 earnings per share (EPS) estimates for Astrazeneca in a research note issued on Wednesday, August 5th. Erste Group Bank analyst H. Engel now expects that the company will earn $11.42 per share for the year, down from their previous estimate of $11.50. The consensus estimate for Astrazeneca's current full-year earnings is $10.22 per share.

A number of other brokerages have also commented on AZN. Weiss Ratings lowered shares of Astrazeneca from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Tuesday, July 28th. HSBC lowered Astrazeneca from a "buy" rating to a "hold" rating in a report on Monday, July 13th. Wall Street Zen downgraded Astrazeneca from a "buy" rating to a "hold" rating in a report on Saturday, August 1st. Barclays restated a "buy" rating on shares of Astrazeneca in a report on Monday, June 1st. Finally, Deutsche Bank Aktiengesellschaft reiterated a "sell" rating on shares of Astrazeneca in a report on Tuesday, June 30th. Twelve investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Astrazeneca currently has an average rating of "Moderate Buy" and a consensus target price of $211.00.

Astrazeneca Price Performance

Astrazeneca stock opened at $161.28 on Monday. The stock has a market cap of $250.12 billion, a price-to-earnings ratio of 24.11, a price-to-earnings-growth ratio of 1.39 and a beta of 0.26. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.89 and a quick ratio of 0.67. Astrazeneca has a 1 year low of $145.79 and a 1 year high of $212.71. The firm has a 50-day moving average of $176.34 and a two-hundred day moving average of $187.13.

Astrazeneca (NYSE:AZN - Get Free Report) last posted its quarterly earnings data on Monday, July 27th. The company reported $2.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.50 by $0.13. Astrazeneca had a return on equity of 31.45% and a net margin of 17.02%.The company had revenue of $15.38 billion during the quarter, compared to analysts' expectations of $15.44 billion. During the same quarter in the previous year, the business earned $2.17 EPS. Astrazeneca's revenue was up 6.4% compared to the same quarter last year.

Institutional Investors Weigh In On Astrazeneca

A number of hedge funds have recently made changes to their positions in AZN. Triumph Capital Management purchased a new stake in Astrazeneca during the third quarter valued at approximately $25,000. MV Capital Management Inc. acquired a new stake in Astrazeneca in the fourth quarter valued at approximately $26,000. Mascoma Wealth Management LLC purchased a new position in Astrazeneca in the first quarter worth $26,000. Roxbury Financial LLC purchased a new position in Astrazeneca in the second quarter worth $29,000. Finally, Eagle Bay Advisors LLC acquired a new position in shares of Astrazeneca during the fourth quarter worth $30,000. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source